These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 6137226)

  • 21. Decreased lymphocyte beta-adrenergic-receptor density in patients with heart failure and tolerance to the beta-adrenergic agonist pirbuterol.
    Colucci WS; Alexander RW; Williams GH; Rude RE; Holman BL; Konstam MA; Wynne J; Mudge GH; Braunwald E
    N Engl J Med; 1981 Jul; 305(4):185-90. PubMed ID: 6113543
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Milrinone in heart failure. Effects on exercise haemodynamics during short term treatment.
    Timmis AD; Smyth P; Jewitt DE
    Br Heart J; 1985 Jul; 54(1):42-7. PubMed ID: 4015915
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative pharmacology and clinical efficacy of newer agents in treatment of heart failure.
    Taylor CR; Baird JR; Blackburn KJ; Cambridge D; Constantine JW; Ghaly MS; Hayden ML; McIlhenny HM; Moore PF; Olukotun AY; Pullman LG; Salsburg DS; Saxton CA; Shevde S
    Am Heart J; 1981 Sep; 102(3 Pt 2):515-32. PubMed ID: 7023221
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Acute and long-term effects of pimobendan (UD-CG 115) in NYHA II and III heart failure. Results of a randomized multicenter double-blind study].
    Assmann I; Kassel P; Duck HG; Fiehring H; Morgan P; Schmidt PK; Höfs T; Nehmiz G
    Z Kardiol; 1991 Nov; 80(11):687-94. PubMed ID: 1792811
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Are the clinical benefits of oral prenalterol in ischaemic heart failure due to beta blockade? A six month randomised double blind comparison with placebo.
    Glover DR; Wathen CG; Murray RG; Petch MC; Muir AL; Littler WA
    Br Heart J; 1985 Feb; 53(2):208-15. PubMed ID: 2857088
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long term haemodynamic, pulmonary function and symptomatic effects of pirbuterol in COPD.
    Neilly JB; Carter R; Tweddel A; Martin W; Hutton I; Banham SW; Stevenson RD
    Respir Med; 1989 Jan; 83(1):59-65. PubMed ID: 2511610
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of xamoterol on resting and exercise haemodynamics in patients with chronic heart failure.
    Virk SJ; Davies MK
    Br J Clin Pharmacol; 1989; 28 Suppl 1(Suppl 1):15S-22S. PubMed ID: 2572250
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The clinical use of inotropes in cardiac failure: dopamine, dobutamine, prenalterol and pirbuterol.
    Rae AP; Tweddel AC; Hutton I
    Herz; 1983 Feb; 8(1):23-33. PubMed ID: 6832690
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acute intravenous and sustained oral treatment with the beta1 agonist prenalterol in patients with chronic severe cardiac failure.
    Currie PJ; Kelly MJ; Middlebrook K; Federman J; Sainsbury E; Ashley J; Pitt A
    Br Heart J; 1984 May; 51(5):530-8. PubMed ID: 6326784
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of felodipine in chronic congestive heart failure: a placebo controlled haemodynamic study at rest and during exercise and orthostatic stress.
    Kassis E; Amtorp O; Waldorff S; Fritz-Hansen P
    Br Heart J; 1987 Nov; 58(5):505-11. PubMed ID: 3314956
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute haemodynamic effects of oral prenalterol in severe heart failure.
    Petch MC; Wisbey C; Ormerod O; Scott C; Goodfellow RM
    Br Heart J; 1984 Jul; 52(1):49-52. PubMed ID: 6146324
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Milrinone for long-term therapy of severe heart failure: clinical experience with special reference to maximal exercise tolerance.
    LeJemtel TH; Gumbardo D; Chadwick B; Rutman HI; Sonnenblick EH
    Circulation; 1986 Mar; 73(3 Pt 2):III213-8. PubMed ID: 3510777
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Acute and chronic effects of oral cardiotonic agent, denopamine (TA-064) in patients with heart failure].
    Inden M; Yamamuro M; Murayama S; Noda E; Tanimura H; Takasaki H; Konishi T; Nakano T; Takezawa H
    Kokyu To Junkan; 1986 May; 34(5):541-6. PubMed ID: 3738247
    [No Abstract]   [Full Text] [Related]  

  • 34. Ischaemic left ventricular failure: evidence of sustained benefit after 18 months' treatment with xamoterol.
    Vigholt-Sørensen E; Faergeman O
    Br Heart J; 1990 Sep; 64(3):186-9. PubMed ID: 1976339
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term digitalis therapy improves left ventricular function in heart failure.
    Arnold SB; Byrd RC; Meister W; Melmon K; Cheitlin MD; Bristow JD; Parmley WW; Chatterjee K
    N Engl J Med; 1980 Dec; 303(25):1443-8. PubMed ID: 6776403
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acute and long-term hemodynamic effects of oral pirbuterol in patients with chronic severe congestive heart failure: randomized double-blind trial.
    Pamelia FX; Gheorghiade M; Beller GA; Bishop HL; Olukotun AY; Taylor CR; Watson DD; Grunwald AM; Sirowatka J; Carabello BA
    Am Heart J; 1983 Dec; 106(6):1369-76. PubMed ID: 6359846
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effects of xamoterol in moderate cardiac insufficiency].
    Kayanakis JG; Larouchi L; Doat P; Grenet B; Fauvel JM; Bounhoure JP
    Presse Med; 1989 Apr; 18(13):667-70. PubMed ID: 2566161
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Amrinone. A preliminary review of its pharmacological properties and therapeutic use.
    Ward A; Brogden RN; Heel RC; Speight TM; Avery GS
    Drugs; 1983 Dec; 26(6):468-502. PubMed ID: 6360634
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Haemodynamic effects of felodipine in congestive heart failure.
    Held P; Swedberg K
    Drugs; 1987; 34 Suppl 3():81-4. PubMed ID: 3443068
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Ibopamine--clinical results].
    Kleber FX
    Z Kardiol; 1991; 80 Suppl 8():71-6. PubMed ID: 1686695
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.